University, Diss., 2005--Würzburg. / Erscheinungsjahr an der Haupttitelstelle: 2005.

Würzburg, Univ., Diss., 2009. / Zsfassung in engl. Sprache.

A T helper cell clone, referred to as clone 9, was derived from an allogeneic mixed lymphocyte culture. Clone 9, as well as supernatant factor(s) derived from it, could help the cytotoxic T lymphocyte (CTL) responses of H-2 Db (Db) responder cells to alloantigens, or they could help the CTL responses of non- Db responder cells to Db alloantigens. Clone 9 cells or their factor(s) were active only when added during the first 24 hours of a five-day culture period. Clone 9 or its factor(s) could also synergize with interleukin-2 (IL-2)-containing medium in mounting cytotoxic responses to alloantigens. The helper activity in clone 9 supernatant was not due to IL-2 and it was specifically absorbed out by Db -spleen cells. The characterization of the Db -specific helper factor(ASHF) was facilitated by the isolation of a T hybridoma clone (clone 25), obtained from fusion of clone 9 cells with the T cell lymphoma, BW5147, and a B cell hybridoma that produced an IgM monoclonal antibody (clone 30 IgM) which bound ASHF. An additional monoclonal antibody (F23.1), which recognizes a determinant of the Vβ8 family of the T cell receptor, was also particularly useful for the characterization of ASHF. Analysis with these reagents showed that both clone 30 IgM and F23.1 immunoadsorbents could retain ASHF activity. Preabsorption of the ASHF with Db spleen cells prior to affinity purification over a clone 30 IgM column resulted in the absorption of Db-specific helper activity as well as the loss of a 50,000 molecular weight (MW) band on SDS-PAGE under reducing conditions. Furthermore, affinity purification of ASHF over the F23.1 immunoadsorbent, but not an irrelevant monoclonal antibody (mAb) column, also yielded a 50,000 MW molecule. Taken together, these findings suggest that the 50,000 MW molecule is a component of the ASHF and it is intimately related to the B chain of the T-cell receptor. The mode of action of clone 9 and its products in the induction bfCTL responses was also investigated. It was found that clone 9 and ASHF could help CTL responses by inducing IL-2 production in B6-stimulated cultures. In addition to ASHF, clone 9 cells also produced an additional factor(s) which participated in the induction of CTL responses. This additional factor(s) was referred to as IL-X. IL-X synergized with excess human recombinant IL-2 in the activation of CTL precursors (CTL-P) in the absence of antigenic stimulation. A model which involves the participation of ASHF, T helper cells, IL-2 and IL-X in the induction of CTL responses is proposed. / Science, Faculty of / Microbiology and Immunology, Department of / Graduate

Mycobacterium tuberculosis (Mtb) causes human tuberculosis, and more people die of it than of any other pathogen in the world. Immunodominant antigens elicit the large majority of T cells during an infection, making them logical vaccine candidates. Yet, it is still unknown whether these immunodominant antigen-specific T cells recognize Mtb-infected cells. Two immunodominant antigens, TB10.4 and Ag85b, have been incorporated into vaccine strategies. Surprisingly, mice vaccinated with TB10.4 generate TB10.4-specific memory CD8+ T cells but do not lead to additional protection compared to unvaccinated mice during TB. Ag85b-specific CD4+ T cells are also generated during vaccination, but the literature on whether these cells recognize Mtb-infected cells is also inconsistent. We demonstrate that TB10.4-specific CD8+ T cells do not recognize Mtb-infected cells. However, under the same conditions, Ag85b-specific CD4+ T cells recognize Mtb-infected macrophages and inhibit bacterial growth. In contrast, polyclonal CD4+ and CD8+ T cells from the lungs of infected mice can specifically recognize Mtb-infected macrophages, suggesting macrophages present antigens other than the immunodominant TB10.4. The antigen location may also be critical for presentation to CD8+ T cells, and live Mtb may inhibit antigen presentation of TB10.4. Finally, we propose that TB10.4 is a decoy antigen as it elicits a robust CD8+ T cell response that poorly recognizes Mtb-infected macrophages, allowing Mtb to evade host immunity.

Es sollten Checkpoint inhibierende anti-TNFRSF Rezeptor Antikörper-Fusionsproteine hergestellt und charakterisiert werden. Die agonistische Aktivität TNFR-spezifischer Antikörper wird maßgeblich durch eine Immobilisation über Fcγ-Rezeptoren beeinflusst. In dieser Arbeit erfolgte die Immobilisation der Antikörper-Fusionsproteine über den PD-L1. In funktionellen Assays konnte eine Aktivitätssteigerung der TNFR-spezifischen Domänen mittels PD-L1 vermittelter Immobilisation gezeigt werden. / Checkpoint inhibiting anti-TNFRSF receptor antibody fusion proteins should be prepared and characterized. The agonistic activity of TNFR-specific antibodies is significantly influenced by immobilization via Fcγ receptors. In this work, immobilization of the antibody fusion proteins was performed via the PD-L1. Functional assays revealed an increase in activity of TNFR-specific domains using PD-L1-mediated immobilization.

Trotz zahlreicher Fortschritte im Verständnis der Funktionsweise des kostimulatorischen Rezeptors CD28 in Mensch, Maus, Ratte und Makake ist nach wie vor wenig hierüber in Bezug auf das Tiermodell Schwein bekannt. Die vorliegende Arbeit untersucht die Funktion und Expression von CD28 in Schweine-T-Zellen sowie die Regulierbarkeit der T-Zellaktivierung durch anti-pCD28 mAb. Die Ergebnisse zeigen, dass hierbei vor allem CD4+ und CD8+ T-Zellen differenziert betrachtet werden müssen. Grundsätzlich unterscheiden sich die beiden T-Zellpopulationen in der CD28 mRNA Expression, im Expressionsverhältnis zwischen CD28 mRNA und Protein, sowie im proliferativen Ansprechen auf anti-pCD28mAb. So reagierten CD4+ im Vergleich zu CD8+ T-Zellen auf die kostimulatorische Inkubation mit anti-pCD28 mAb des Klons 3D11 sensibler. In direkt stimulatorischen Ansätzen zeigte sich, dass CD4+ und CD8+ T-Zellen durch unterschiedliche anti-pCD28 mAb differentiell angesprochen werden können. Eine superagonistische Funktion konnte für CD4+ T-Zell aktivierende anti-pCD28 mAb in den bisherigen Versuchen noch nicht beobachtet werden. Letzteres ist hierbei vor allem für den Transfer von vielversprechenden Therapiestrategien vom Kleintier- zum Großtiermodell auf dem Weg zur Entwicklung neuer Therapieoptionen für Autoimmunerkrankungen, Erkrankungen mit starker proinflammatorischer Aktivität und dem Myokardinfarkt von Bedeutung. / Even though tremendous progress has been made in clarifying the function of the costimulatory receptor CD28 in human, mouse, rat, and macaques, concerning pigs, an important large animal model, only little is still known about CD28 expression and function. Therefore, our work aimed at investigating the function and expression of CD28 in porcine T cells as well as the applicability of anti-pCD28 mAb as a tool to regulate T cell activation, specifically. Our results indicate that the two major T cell groups, CD4+ and CD8+, have to be considered separately. These cell populations differ in their level of pCD28 mRNA expression, their ratio of CD28 mRNA and protein expression as well as their proliferative responsiveness towards anti-pCD28 mAb. In costimulatory assays, CD4+ compared to CD8+ T cells showed higher sensitivity toward low concentrations of the anti-pCD28 mAb 3D11. Additionally, in direct stimulatory assays, CD4+ and CD8+ T cells can be specifically targeted by different anti-pCD28 mAb. With these assays, a superagonistic anti-pCD28 mAb could not been detected so far. With anti-pCD28 superagonist, promising therapeutic strategies developed in rodents could be tested in pigs as a large animal model, representing the next step on the way towards new therapeutic options for autoim-mune diseases, diseases with strong proinflammatory activity and myocardial infarction.

Antikörper, die gegen eine klinisch relevante Gruppe von Rezeptoren innerhalb der Tumornekrosefaktor-Rezeptor-Superfamilie (TNFRSF) gerichtet sind, darunter CD40 und CD95 (Fas/Apo-1), benötigen ebenfalls eine Bindung an Fc-Gamma-Rezeptoren (FcγRs), um eine starke agonistische Wirkung zu entfalten. Diese FcγR-Abhängigkeit beruht weitgehend auf der bloßen zellulären Verankerung durch die Fc-Domäne des Antikörpers und benötigt dabei kein FcγR-Signalling. Ziel dieser Doktorarbeit war es, das agonistische Potenzial von αCD40- und αCD95-Antikörpern unabhängig von der Bindung an FcγRs durch die Verankerung an Myelomzellen zu entfalten. Zu diesem Zweck wurden verschiedene Antikörpervarianten (IgG1, IgG1-N297A, Fab2) gegen die TNFRSF-Mitglieder CD40 und CD95 genetisch mit einem einzelkettig kodierten B-Zell-aktivierenden Faktor (scBaff) Trimer als C-terminale myelom-spezifische Verankerungsdomäne fusioniert, welche die Fc-Domäne-vermittelte FcγR-Bindung ersetzt. Diese bispezifischen Antikörper-scBaff-Fusionsproteine wurden in Bindungsstudien und funktionellen Assays mit Tumorzelllinien untersucht, die einen oder mehrere der drei Baff-Rezeptoren exprimieren: BaffR, Transmembran-Aktivator und CAML-Interaktor (TACI) und B-Zell-Reifungsantigen (BCMA). Zelluläre Bindungsstudien zeigten, dass die Bindungseigenschaften der verschiedenen Domänen innerhalb der Antikörper-scBaff-Fusionen gegenüber der Zielantigene vollständig intakt blieben. In Ko-Kulturversuchen von CD40- und CD95-responsiven Zellen mit BaffR-, BCMA- oder TACI-exprimierenden Verankerungszellen zeigten die Antikörper-Fusionsproteine einen starken Agonismus, während in Ko-Kulturen mit Zellen ohne Expression von Baff-interagierenden Rezeptoren nur eine geringe Rezeptorstimulation beobachtet wurde. Die hier vorgestellten αCD40- und αCD95-Antikörper-scBaff-Fusionsproteine zeigen also Myelom-spezifische Aktivität und versprechen im Vergleich zu herkömmlichen CD40- und CD95-Agonisten geringere systemische Nebenwirkungen. / Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity. This FcγR dependency largely relies on the mere cellular anchoring through the antibody's Fc domain and does not involve the engagement of FcγR signaling. The aim of this doctoral thesis was to elicit agonistic activity from αCD40 and αCD95 antibodies in a myeloma cell anchoring-controlled FcγR-independent manner. For this purpose, various antibody variants (IgG1, IgG1-N297A, Fab2) against the TNFRSF members CD40 and CD95 were genetically fused to a single-chain-encoded B-cell activating factor (scBaff) trimer as a C-terminal myeloma-specific anchoring domain substituting for Fc domain-mediated FcγR binding. These bispecific antibody-scBaff fusion proteins were evaluated in binding studies and functional assays using tumor cell lines expressing one or more of the three receptors of Baff: BaffR, transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). Cellular binding studies showed that the binding properties of the different domains within the fusion proteins remained fully intact in the antibody-scBaff fusion proteins. In co-culture assays of CD40- and CD95-responsive cells with BaffR, BCMA or TACI expressing anchoring cells, the antibody fusion proteins displayed strong agonism while only minor receptor stimulation was observed in co-cultures with cells without expression of Baff-interacting receptors. Thus, the herein presented αCD40 and αCD95 antibody fusion proteins display myeloma cell-dependent activity and promise reduced systemic side effects compared to conventional CD40 and CD95 agonists.

Human cells transformed by SV40 large T antigen achieve an extended lifespan and continue to grow and divide past the normal growth limit. This extended lifespan often ends at crisis when the cells die through fatal cell division. A few cells will survive this crisis and continue to proliferate indefinitely and are therefore considered immortal. Transformation of cells by SV40 large T antigen is associated with the induction of genomic instability at early times. This instability may contribute to a cells surviving crisis and becoming immortal through the chance disruption of genes involved in cell proliferation and regulation of cell death. Genetic instability is also observed in human tumours and the mechanisms by which it occurs both in tumour cells and SV40 transformed cells may be similar. In order to investigate these mechanisms, human and rodent cells were transfected with wild type and mutant forms of SV40 large T antigen and analyzed cytogenetically. The results of this study demonstrate that the amino terminal 147 amino acids of SV40 large T antigen are sufficient for the induction of genomic instability and at least three regions within this amino terminal fragment are necessary. One between amino acids 17 and 27. A second being the retinoblastoma protein binding site, and the third between amino acids 130 and 147. Finally, binding of T antigen to p53 appears to not be required for the induction of genomic instability, but may be necessary for the survival of aberrant cells. There is an apparent correspondence between the ability of T antigen mutants to induce genomic instability, and their abilities to induce cellular DNA synthesis and to transform and immortalize cells. / Thesis / Master of Science (MS)

The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from PDF of title page (University of Missouri--Columbia, viewed on April 1, 2010). Vita. Thesis advisor: Habib Zaghouani. "May 2008" Includes bibliographical references.

No description available.